Core Viewpoint - The company, Silver Noble Pharmaceuticals-B (02591), has announced that its H-shares will be included in the eligible securities list for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, effective from December 8, 2025, which is expected to enhance its investor base and trading liquidity [1] Group 1 - The inclusion of H-shares in the Stock Connect programs allows qualified investors from mainland China to directly invest in H-shares through the Shanghai and Shenzhen stock exchanges [1] - The board believes that this inclusion will further expand the company's investor base and increase the trading liquidity of H-shares [1] - The anticipated outcome is an enhancement of the investment value of H-shares and an improvement in the company's reputation in the capital markets [1]
银诺医药-B(02591)：H股获纳入沪港通及深港通合资格证券名单